Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/116941
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorMartín, Rubén-
dc.contributor.authorCordova, Claudia-
dc.contributor.authorSan Román, José Alberto-
dc.contributor.authorGutiérrez, Beatriz-
dc.contributor.authorCachofeiro, Victoria-
dc.contributor.authorNieto, María Luisa-
dc.date.accessioned2015-06-22T09:21:41Z-
dc.date.available2015-06-22T09:21:41Z-
dc.date.issued2014-
dc.identifierdoi: 10.1016/j.yjmcc.2014.04.002-
dc.identifierissn: 0022-2828-
dc.identifiere-issn: 1095-8584-
dc.identifier.citationJournal of Molecular and Cellular Cardiology 72: 250-262 (2014)-
dc.identifier.urihttp://hdl.handle.net/10261/116941-
dc.description.abstractMyocarditis and dilated cardiomyopathy (DCM) are inflammatory diseases of the myocardium, for which appropriate treatment remains a major clinical challenge. Oleanolic acid (OA), a natural triterpene widely distributed in food and medicinal plants, possesses a large range of biological effects with beneficial properties for health and disease prevention. Several experimental approaches have shown its cardioprotective actions, and OA has recently been proven effective for treating Th1 cell-mediated inflammatory diseases; however, its effect on inflammatory heart disorders, including myocarditis, has not yet been addressed. Therefore, the present study was undertaken to determine the effectiveness of OA in prevention and treatment of experimental autoimmune myocarditis (EAM). The utility of OA was evaluated in vivo through their administration to cardiac α-myosin (MyHc-α614-629)-immunized BALB/c mice from day 0 or day 21 post-immunization to the end of the experiment, and in vitro through their addition to stimulated-cardiac cells. Prophylactic and therapeutic administration of OA dramatically decreased disease severity: the heart weight/body weight ratio as well as plasma levels of brain natriuretic peptide and myosin-specific autoantibodies production were significantly reduced in OA-treated EAM animals, compared with untreated ones. Histological heart analysis showed that OA-treatment diminished cell infiltration, fibrosis and dystrophic calcifications. OA also decreased proliferation of cardiac fibroblast in vitro and attenuated calcium and collagen deposition induced by relevant cytokines of active myocarditis. Furthermore, in OA-treated EAM mice the number of Treg cells and the production of IL-10 and IL-35 were markedly increased, while proinflammatory and profibrotic cytokines were significantly reduced. We demonstrate that OA ameliorates both developing and established EAM by promoting an antiinflammatory cytokine profile and by interfering with the generation of cardiac-specific autoantibodies, as well as through direct protective effects on cardiac cells. Therefore, we envision this natural product as novel helpful tool for intervention in inflammatory cardiomyopathies including myocarditis. © 2014 Elsevier Ltd.-
dc.description.sponsorshipThis work was supported by Ministerio de Economía y Competitividad (SAF2012-34460), Consejería de la Junta de Castilla y León (BIO 103/VA11/11), Fondo de Investigaciones Sanitarias (PI12/01729), Sara Borrell Programa (to RM) and Junta de Castilla y León FPI Programa (to CC) co-funded by FSE. The authors are members of the Red de Investigación Cardiovascular (RIC; RD12/0042/0033 and RD12/0042/0026).-
dc.publisherElsevier-
dc.rightsclosedAccess-
dc.subjectInflammation-
dc.subjectFibrosis-
dc.subjectCalcification-
dc.subjectTriterpenes-
dc.subjectOleanolic acid-
dc.subjectMyocarditis-
dc.titleOleanolic acid modulates the immune-inflammatory response in mice with experimental autoimmune myocarditis and protects from cardiac injury. Therapeutic implications for the human disease-
dc.typeartículo-
dc.identifier.doi10.1016/j.yjmcc.2014.04.002-
dc.date.updated2015-06-22T09:21:41Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderJunta de Castilla y León-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderRed de Investigación Cardiovascular (España)-
dc.relation.csic-
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100014180es_ES
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.openairetypeartículo-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
Aparece en las colecciones: (IBGM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

SCOPUSTM   
Citations

63
checked on 11-abr-2024

WEB OF SCIENCETM
Citations

56
checked on 28-feb-2024

Page view(s)

299
checked on 17-abr-2024

Download(s)

163
checked on 17-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.